“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”
Abstract Background ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1–3%. In early-stage lung cancer ROS1 might also provide a fruitful target for...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | Diagnostic Pathology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13000-023-01357-1 |
| _version_ | 1797818195279609856 |
|---|---|
| author | Anne Pernille Harlem Dyrbekk Abdirashid Ali Warsame Pål Suhrke Marianne Odnakk Ludahl Joakim Oliu Moe Inger Johanne Zwicky Eide Marius Lund-Iversen Odd Terje Brustugun |
| author_facet | Anne Pernille Harlem Dyrbekk Abdirashid Ali Warsame Pål Suhrke Marianne Odnakk Ludahl Joakim Oliu Moe Inger Johanne Zwicky Eide Marius Lund-Iversen Odd Terje Brustugun |
| author_sort | Anne Pernille Harlem Dyrbekk |
| collection | DOAJ |
| description | Abstract Background ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1–3%. In early-stage lung cancer ROS1 might also provide a fruitful target for neoadjuvant or adjuvant therapy. In the present study, we investigated the prevalence of ROS1 fusion in a Norwegian cohort of early-stage lung cancer. We also explored whether positive ROS1 immunohistochemical (IHC) stain was associated with certain mutations, clinical characteristics and outcomes. Methods The study was performed using biobank material from 921 lung cancer patients including 542 patients with adenocarcinoma surgically resected during 2006–2018. Initially, we screened the samples with two different IHC clones (D4D6 and SP384) targeting ROS1. All samples that showed more than weak or focal staining, as well as a subgroup of negative samples, were analyzed with ROS1 fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) with a comprehensive NGS DNA and RNA panel. Positive ROS1-fusion was defined as those samples positive in at least two of the three methods (IHC, FISH, NGS). Results Fifty cases were IHC positive. Of these, three samples were both NGS and FISH-positive and considered positive for ROS1 fusion. Two more samples were FISH positive only, and whilst IHC and NGS were negative. These were also negative with Reverse Transcription quantitative real time Polymerase Chain Reaction (RT-qPCR). The prevalence of ROS1 fusion in adenocarcinomas was 0.6%. All cases with ROS1 fusion had TP53 mutations. IHC-positivity was associated with adenocarcinoma. Among SP384-IHC positive cases we also found an association with never smoking status. There was no association between positive IHC and overall survival, time to relapse, age, stage, sex or pack-year of smoking. Conclusions ROS1 seems to be less frequent in early-stage disease than in advanced stages. IHC is a sensitive, but less specific method and the results need to be confirmed with another method like FISH or NGS. |
| first_indexed | 2024-03-13T09:04:33Z |
| format | Article |
| id | doaj.art-36926be6be1c4199a84064f4db86b336 |
| institution | Directory Open Access Journal |
| issn | 1746-1596 |
| language | English |
| last_indexed | 2024-03-13T09:04:33Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Diagnostic Pathology |
| spelling | doaj.art-36926be6be1c4199a84064f4db86b3362023-05-28T11:07:12ZengBMCDiagnostic Pathology1746-15962023-05-0118111310.1186/s13000-023-01357-1“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”Anne Pernille Harlem Dyrbekk0Abdirashid Ali Warsame1Pål Suhrke2Marianne Odnakk Ludahl3Joakim Oliu Moe4Inger Johanne Zwicky Eide5Marius Lund-Iversen6Odd Terje Brustugun7University of OsloDepartment of Pathology, Oslo University Hospital, The Norwegian Radium HospitalDepartment of Pathology, Vestfold Hospital TrustDepartment of Microbiology/ Division for Genetechnology, Vestfold Hospital TrustDepartment of Internal Medicine, Vestfold Hospital TrustUniversity of OsloDepartment of Pathology, Oslo University Hospital, The Norwegian Radium HospitalUniversity of OsloAbstract Background ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1–3%. In early-stage lung cancer ROS1 might also provide a fruitful target for neoadjuvant or adjuvant therapy. In the present study, we investigated the prevalence of ROS1 fusion in a Norwegian cohort of early-stage lung cancer. We also explored whether positive ROS1 immunohistochemical (IHC) stain was associated with certain mutations, clinical characteristics and outcomes. Methods The study was performed using biobank material from 921 lung cancer patients including 542 patients with adenocarcinoma surgically resected during 2006–2018. Initially, we screened the samples with two different IHC clones (D4D6 and SP384) targeting ROS1. All samples that showed more than weak or focal staining, as well as a subgroup of negative samples, were analyzed with ROS1 fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) with a comprehensive NGS DNA and RNA panel. Positive ROS1-fusion was defined as those samples positive in at least two of the three methods (IHC, FISH, NGS). Results Fifty cases were IHC positive. Of these, three samples were both NGS and FISH-positive and considered positive for ROS1 fusion. Two more samples were FISH positive only, and whilst IHC and NGS were negative. These were also negative with Reverse Transcription quantitative real time Polymerase Chain Reaction (RT-qPCR). The prevalence of ROS1 fusion in adenocarcinomas was 0.6%. All cases with ROS1 fusion had TP53 mutations. IHC-positivity was associated with adenocarcinoma. Among SP384-IHC positive cases we also found an association with never smoking status. There was no association between positive IHC and overall survival, time to relapse, age, stage, sex or pack-year of smoking. Conclusions ROS1 seems to be less frequent in early-stage disease than in advanced stages. IHC is a sensitive, but less specific method and the results need to be confirmed with another method like FISH or NGS.https://doi.org/10.1186/s13000-023-01357-1Lung cancerROS1Targeted therapyNGSImmunohistochemistry |
| spellingShingle | Anne Pernille Harlem Dyrbekk Abdirashid Ali Warsame Pål Suhrke Marianne Odnakk Ludahl Joakim Oliu Moe Inger Johanne Zwicky Eide Marius Lund-Iversen Odd Terje Brustugun “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” Diagnostic Pathology Lung cancer ROS1 Targeted therapy NGS Immunohistochemistry |
| title | “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” |
| title_full | “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” |
| title_fullStr | “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” |
| title_full_unstemmed | “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” |
| title_short | “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” |
| title_sort | evaluation of ros1 expression and rearrangements in a large cohort of early stage lung cancer |
| topic | Lung cancer ROS1 Targeted therapy NGS Immunohistochemistry |
| url | https://doi.org/10.1186/s13000-023-01357-1 |
| work_keys_str_mv | AT annepernilleharlemdyrbekk evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT abdirashidaliwarsame evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT palsuhrke evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT marianneodnakkludahl evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT joakimoliumoe evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT ingerjohannezwickyeide evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT mariuslundiversen evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer AT oddterjebrustugun evaluationofros1expressionandrearrangementsinalargecohortofearlystagelungcancer |